ALK and non-small cell lung carcinoma: It effectively suppresses resistance mutations such as Leu1196Met and Cys1156Tyr, demonstrating significant in vitro and in vivo efficacy in ALK-positive NSCLC, particularly in chemotherapy-pretreated but ALK-TKI-naïve patients [7].